固定的位置对二酸盐作为日拉尼尔日拉尼尔二酸盐合成酶抑制剂的活性的影响
Md Ayub Ali1, Mona A Maalouf2, Dan Feng3
1Department of Chemistry, University of Iowa, Iowa City, IA 52242-1294, USA; Department of Chemistry, Bangladesh University of Engineering and Technology (BUET), Dhaka 1000, Bangladesh.
Bioorganic & medicinal chemistry
|March 5, 2025
概括
新型双酸盐抑制剂向格兰二酸盐合成酶 (GGDPS) 显示了复杂的结构-活性关系. 细胞效能有显著的变化,这表明膜载体在GGDPS抑制剂吸收中的作用.
科学领域:
- 药用化学 医学化学
- 癌症生物学 癌症生物学
- 酶抑制可以抑制酶.
背景情况:
- 格拉尼尔格拉尼尔二酸合成酶 (GGDPS) 对于蛋白质格拉尼尔格拉尼化至关重要.
- 抑制GGDPS提供了一种针对骨髓瘤和骨髓瘤等癌症的新策略.
- 了解GGDPS抑制剂的结构-活性关系 (SAR) 是药物开发的关键.
研究的目的:
- 为了合成和评估新型异oprenoid triazole 双酸衍生物作为GGDPS 抑制剂.
- 研究这些抑制剂在酶,细胞和生物水平上的复杂SAR.
- 探索结构修改对GGDPS抑制和细胞活动的影响.
主要方法:
- 合成具有多种异oprenoid 链和α-碳修饰的新型双酸衍生物.
- 酶分析测试以确定与GGDPS相比的IC50值.
- 使用人类骨髓瘤和骨髓瘤细胞系进行细胞检测,以评估功效.
- 结构-活性关系的分析,包括前药物和膜透性研究.
主要成果:
- 类人烯衍生物显著降低了酶和细胞活性.
- 同聚甘/同聚甘衍生物表现出类似的酶抑制,但细胞功效不同.
- 细胞功效受烯立体化学,α-碳修饰和瘤细胞类型的影响.
- 研究结果表明,膜载体介导细胞吸收GGDPS抑制剂.
结论:
- GGDPS抑制剂的SAR是复杂的,受结构特征和细胞吸收机制的影响.
- 特定的膜载体可能在这些化合物的细胞活性中发挥关键作用.
- 对这些载体的进一步研究将提高对GGDPS向癌症疗法的理解和开发.
相关概念视频
02:54Protein Kinases and Phosphatases
13.0K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
13.0K
01:42Phosphoinositides and PIPs
7.7K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
7.7K
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
124
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
124
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.5K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.5K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
142
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
142